Literature DB >> 19571723

Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy.

Benoît Marin1, Rodolphe Thiébaut, Heiner C Bucher, Virginie Rondeau, Dominique Costagliola, Maria Dorrucci, Osamah Hamouda, Maria Prins, Sarah Walker, Kholoud Porter, Caroline Sabin, Geneviève Chêne.   

Abstract

OBJECTIVE: To assess whether immunodeficiency is associated with the most frequent non-AIDS-defining causes of death in the era of combination antiretroviral therapy (cART).
DESIGN: Observational multicentre cohorts.
METHODS: Twenty-three cohorts of adults with estimated dates of human immunodeficiency virus (HIV) seroconversion were considered. Patients were seroconverters followed within the cART era. Measurements were latest CD4, nadir CD4 and time spent with CD4 cell count less than 350 cells/microl. Outcomes were specific causes of death using a standardized classification.
RESULTS: Among 9858 patients (71 230 person-years follow-up), 597 died, 333 (55.7%) from non-AIDS-defining causes. Non-AIDS-defining infection, liver disease, non-AIDS-defining malignancy and cardiovascular disease accounted for 53% of non-AIDS deaths. For each 100 cells/microl increment in the latest CD4 cell count, we found a 64% (95% confidence interval 58-69%) reduction in risk of death from AIDS-defining causes and significant reductions in death from non-AIDS infections (32, 18-44%), end-stage liver disease (33, 18-46%) and non-AIDS malignancies (34, 21-45%). Non-AIDS-defining causes of death were also associated with nadir CD4 while being cART-naive or duration of exposure to immunosuppression. No relationship between risk of death from cardiovascular disease and CD4 cell count was found though there was a raised risk associated with elevated HIV RNA.
CONCLUSION: In the cART era, the most frequent non-AIDS-defining causes of death are associated with immunodeficiency, only cardiovascular disease was associated with high viral replication. Avoiding profound and mild immunodeficiency, through earlier initiation of cART, may impact on morbidity and mortality of HIV-infected patients.

Entities:  

Mesh:

Year:  2009        PMID: 19571723      PMCID: PMC3305466          DOI: 10.1097/QAD.0b013e32832e9b78

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  50 in total

1.  Comments on 'Analysing and interpreting competing risk data'.

Authors:  A Latouche; J Beyersmann; J P Fine
Journal:  Stat Med       Date:  2007-08-30       Impact factor: 2.373

2.  Survival after introduction of HAART in people with known duration of HIV-1 infection. The CASCADE Collaboration. Concerted Action on SeroConversion to AIDS and Death in Europe.

Authors: 
Journal:  Lancet       Date:  2000-04-01       Impact factor: 79.321

3.  Pre-AIDS mortality and its association with HIV disease progression in haemophilic men, injecting drug users and homosexual men.

Authors:  M Prins; C A Sabin; C A Lee; H Devereux; R A Coutinho
Journal:  AIDS       Date:  2000-08-18       Impact factor: 4.177

4.  Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994-1998.

Authors:  Janice K Louie; Ling Chin Hsu; Dennis H Osmond; Mitchell H Katz; Sandra K Schwarcz
Journal:  J Infect Dis       Date:  2002-09-13       Impact factor: 5.226

5.  Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study.

Authors:  A Mocroft; R Brettle; O Kirk; A Blaxhult; J M Parkin; F Antunes; P Francioli; A D'Arminio Monforte; Z Fox; J D Lundgren
Journal:  AIDS       Date:  2002-08-16       Impact factor: 4.177

6.  Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998-1999.

Authors:  F Bonnet; P Morlat; G Chêne; P Mercié; D Neau; I Chossat; M Decoin; F Djossou; J Beylot; F Dabis
Journal:  HIV Med       Date:  2002-07       Impact factor: 3.180

7.  Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy.

Authors:  Mardge H Cohen; Audrey L French; Lorie Benning; Andrea Kovacs; Kathryn Anastos; Mary Young; Howard Minkoff; Nancy A Hessol
Journal:  Am J Med       Date:  2002-08-01       Impact factor: 4.965

8.  CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection.

Authors:  Jason V Baker; Grace Peng; Joshua Rapkin; Donald I Abrams; Michael J Silverberg; Rodger D MacArthur; Winston P Cavert; W Keith Henry; James D Neaton
Journal:  AIDS       Date:  2008-04-23       Impact factor: 4.177

9.  Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks.

Authors:  Abdel Babiker; Janet Darbyshire; Patrizio Pezzotti; Kholoud Porter; Giovanni Rezza; Sarah A Walker; Valerie Beral; Roel Coutinho; Julia Del Amo; Noël Gill; Christine Lee; Laurence Meyer; Freya Tyrer; Francois Dabis; Rodolphe Thiebaut; Sylvie Lawson-Aye; Faroudy Boufassa; Osamah Hamouda; Klaus Fischer; Patrizio Pezzotti; Giovanni Rezza; Giota Touloumi; Angelos Hatzakis; Anastasia Karafoulidou; Olga Katsarou; Ray Brettle; Jorge del Romero; Maria Prins; Birgit van Benthem; Ole Kirk; Court Pederson; Idelfonso Hernández Aguado; Santiago Pérez-Hoyos; Anne Eskild; Johan N Bruun; Mette Sannes; Caroline Sabin; Christine Lee; Anne M Johnson; Andrew N Phillips; Patrick Francioli; Philippe Vanhems; Mathias Egger; Martin Rickenbach; David Cooper; John Kaldor; Lesley Ashton; Jeanette Vizzard; Roberto Muga; Nicholas E Day; Daniela De Angelis
Journal:  Int J Epidemiol       Date:  2002-10       Impact factor: 7.196

10.  HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies.

Authors:  Antonella d'Arminio Monforte; Donald Abrams; Christian Pradier; Rainer Weber; Peter Reiss; Fabrice Bonnet; Ole Kirk; Matthew Law; Stephane De Wit; Nina Friis-Møller; Andrew N Phillips; Caroline A Sabin; Jens D Lundgren
Journal:  AIDS       Date:  2008-10-18       Impact factor: 4.632

View more
  104 in total

1.  Considerations for Endpoint Selection When Designing HIV Clinical Trials.

Authors:  Katherine Huppler Hullsiek; Birgit Grund
Journal:  Curr Infect Dis Rep       Date:  2012-02       Impact factor: 3.725

2.  Antiretroviral therapy for tuberculosis control in nine African countries.

Authors:  Brian G Williams; Reuben Granich; Kevin M De Cock; Philippe Glaziou; Abhishek Sharma; Christopher Dye
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-25       Impact factor: 11.205

3.  Interleukin-37 Expression Is Increased in Chronic HIV-1-Infected Individuals and Is Associated with Inflammation and the Size of the Total Viral Reservoir.

Authors:  Jesper F Højen; Thomas A Rasmussen; Karen Lise D Andersen; Anni A Winckelmann; Rune R Laursen; Jesper D Gunst; Holger J Møller; Mayumi Fujita; Lars Østergaard; Ole S Søgaard; Charles A Dinarello; Martin Tolstrup
Journal:  Mol Med       Date:  2015-04-14       Impact factor: 6.354

4.  HIV status is an independent risk factor for reporting lower urinary tract symptoms.

Authors:  Benjamin N Breyer; Stephen K Van den Eeden; Michael A Horberg; Michael L Eisenberg; Donna Y Deng; James F Smith; Alan W Shindel
Journal:  J Urol       Date:  2011-03-21       Impact factor: 7.450

5.  Risk Factors Associated With Quantitative Evidence of Lung Emphysema and Fibrosis in an HIV-Infected Cohort.

Authors:  Joseph K Leader; Kristina Crothers; Laurence Huang; Mark A King; Alison Morris; Bruce W Thompson; Sonia C Flores; Michael B Drummond; William N Rom; Philip T Diaz
Journal:  J Acquir Immune Defic Syndr       Date:  2016-04-01       Impact factor: 3.731

6.  Age, comorbidities, and AIDS predict a frailty phenotype in men who have sex with men.

Authors:  Keri N Althoff; Lisa P Jacobson; Ross D Cranston; Roger Detels; John P Phair; Xiuhong Li; Joseph B Margolick
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2013-10-14       Impact factor: 6.053

7.  Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy.

Authors:  Tuan Le; Edwina J Wright; Davey M Smith; Weijing He; Gabriel Catano; Jason F Okulicz; Jason A Young; Robert A Clark; Douglas D Richman; Susan J Little; Sunil K Ahuja
Journal:  N Engl J Med       Date:  2013-01-17       Impact factor: 91.245

8.  Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study.

Authors:  Helen Kovari; Caroline A Sabin; Bruno Ledergerber; Lene Ryom; Signe W Worm; Colette Smith; Andrew Phillips; Peter Reiss; Eric Fontas; Kathy Petoumenos; Stéphane De Wit; Philippe Morlat; Jens D Lundgren; Rainer Weber
Journal:  Clin Infect Dis       Date:  2012-10-22       Impact factor: 9.079

9.  RON receptor tyrosine kinase, a negative regulator of inflammation, is decreased during simian immunodeficiency virus-associated central nervous system disease.

Authors:  Daniele C Cary; Janice E Clements; Andrew J Henderson
Journal:  J Immunol       Date:  2013-09-16       Impact factor: 5.422

10.  Rate and predictors of non-AIDS events in a cohort of HIV-infected patients with a CD4 T cell count above 500 cells/mm³.

Authors:  Constanza Lucero; Berta Torres; Agathe León; Marta Calvo; Lorna Leal; Iñaki Pérez; Montserrat Plana; Mireia Arnedo; Josep Mallolas; Josep M Gatell; Felipe García
Journal:  AIDS Res Hum Retroviruses       Date:  2013-04-18       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.